A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype

Iain A M MacPhee; David W Holt

doi:10.1097/TP.0b013e3181609054

A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype

Transplantation. 2008 Jan 27;85(2):163-5. doi: 10.1097/TP.0b013e3181609054.

Authors

Iain A M MacPhee¹, David W Holt

Affiliation

¹ Cellular and Molecular Medicine, Renal Medicine, St. George's, University of London, Cranmer Terrace, London, UK. [email protected]

PMID: 18212618
DOI: 10.1097/TP.0b013e3181609054

Abstract

Pharmacogenetics has the potential to complement therapeutic drug monitoring in achieving target blood concentrations of the immunosuppressive drugs during the critical early period after transplantation when adequate drug exposure is essential to prevent rejection. The most attractive candidate for a pharmacogenetic strategy is tacrolimus dosing based on the CYP3A5 genotype.

MeSH terms

Asian People / genetics
Black People / genetics
Cytochrome P-450 CYP3A
Cytochrome P-450 Enzyme System / genetics*
Gene Expression Regulation, Enzymologic
Genotype
Humans
Immunosuppression Therapy / methods*
Immunosuppressive Agents / therapeutic use
Tacrolimus / therapeutic use
Transplantation Immunology*
United Kingdom
White People / genetics

Substances

Immunosuppressive Agents
Cytochrome P-450 Enzyme System
CYP3A5 protein, human
Cytochrome P-450 CYP3A
Tacrolimus